2,566 results on '"Histocompatibility Testing methods"'
Search Results
2. Characterisation of the novel HLA-A*26:247 allele by sequencing-based typing.
- Author
-
Cargou M, Elsermans V, Top I, Guidicelli G, and Visentin J
- Subjects
- Humans, Codon, Sequence Alignment, Alleles, Exons, Histocompatibility Testing methods, HLA-A Antigens genetics, Sequence Analysis, DNA methods, Base Sequence
- Abstract
HLA-A*26:247 differs from HLA-A*26:01:01:01 by one nucleotide substitution in codon 245 in exon 4., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
3. Characterisation of the novel HLA-DRB3*02:202 allele by sequencing-based typing.
- Author
-
Cargou M, Andreani M, Bianculli AG, Wojciechowski E, and Visentin J
- Subjects
- Humans, Codon, Sequence Alignment, Alleles, Exons, Histocompatibility Testing methods, Sequence Analysis, DNA methods, HLA-DRB3 Chains genetics, Base Sequence
- Abstract
HLA-DRB3*02:202 differs from DRB3*02:112 by one nucleotide substitution in codon 51 in exon 2., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
4. Identification of the novel HLA-DQA1*03:79 allele in a candidate bone marrow donor by next generation sequencing.
- Author
-
Gaballa A, Lundin N, and Eich T
- Subjects
- Humans, Bone Marrow, Polymorphism, Single Nucleotide, Base Sequence, HLA-DQ alpha-Chains genetics, High-Throughput Nucleotide Sequencing, Alleles, Exons, Histocompatibility Testing methods, Tissue Donors
- Abstract
A single nucleotide mismatch within exon 3 of HLA-DQA1 differentiates the novel allele DQA1*03:79 from DQA1*03:15., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
5. Characterisation of the novel HLA-DQB1*05:305 allele using next-generation sequencing.
- Author
-
Chen N, He Y, Dong L, Zhang W, and Zhu F
- Subjects
- Humans, Polymorphism, Single Nucleotide, Histocompatibility Testing methods, Base Sequence, Sequence Analysis, DNA methods, HLA-DQ beta-Chains genetics, Alleles, High-Throughput Nucleotide Sequencing methods, Exons
- Abstract
HLA-DQB1*05:305 shows one single nucleotide substitution at position 664 compared with HLA-DQB1*05:03:01:01., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
6. Identification of the novel HLA-DPB1*21:01:02 allele using nanopore sequencing technology.
- Author
-
Zhang W, Chen N, Pi W, Wang F, and Zhu F
- Subjects
- Humans, Polymorphism, Single Nucleotide, Base Sequence, Sequence Analysis, DNA methods, Tissue Donors, Sequence Alignment, HLA-DP beta-Chains genetics, Alleles, Exons, Histocompatibility Testing methods, Nanopore Sequencing methods
- Abstract
HLA-DPB1*21:01:02 differs from HLA-DPB1*21:01:01 by one single nucleotide substitution at position 435 C>T in exon 3., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
7. High Resolution HLA-A, HLA-B, and HLA-C Allele Frequencies in Romanian Hematopoietic Stem Cell Donors.
- Author
-
Caragea AM, Ursu RI, Maruntelu I, Tizu M, Constantinescu AE, Tălăngescu A, and Constantinescu I
- Subjects
- Humans, Male, Female, Alleles, Romania, Hematopoietic Stem Cells metabolism, Hematopoietic Stem Cell Transplantation, Adult, High-Throughput Nucleotide Sequencing, Histocompatibility Testing methods, Genotype, Middle Aged, HLA-C Antigens genetics, Gene Frequency, HLA-A Antigens genetics, HLA-B Antigens genetics, Tissue Donors
- Abstract
The HLA genes are associated with various autoimmune pathologies, with the control of the immune response also being significant in organs and cells transplantation. The aim of the study is to identify the HLA-A, HLA-B, and HLA-C alleles frequencies in the analyzed Romanian cohort. We performed HLA typing using next-generation sequencing (NGS) in a Romanian cohort to estimate class I HLA allele frequencies up to a six-digit resolution. A total of 420 voluntary donors from the National Registry of Voluntary Hematopoietic Stem Cell Donors (RNDVCSH) were included in the study for HLA genotyping. Peripheral blood samples were taken and brought to the Fundeni Clinical Institute during 2020-2021. HLA genotyping was performed using the Immucor Mia Fora NGS MFlex kit. A total of 109 different alleles were detected in 420 analyzed samples, out of which 31 were for HLA-A, 49 for HLA-B, and 29 for HLA-C. The most frequent HLA-A alleles were HLA-A*02:01:01 (26.11%), HLA-A*01:01:01 (12.5%), HLA-A*24:02:01 (11.67%), HLA-A*03:01:01 (9.72%), HLA-A*11:01:01, and HLA-A*32:01:01 (each with 8.6%). For the HLA-B locus, the most frequent allele was HLA-B*18:01:01 (11.25%), followed by HLA-B*51:01:01 (10.83%) and HLA-B*08:01:01 (7.78%). The most common HLA-C alleles were HLA-C*07:01:01 (17.36%), HLA-C*04:01:01 (13.47%), and HLA-C*12:03:01 (10.69%). Follow-up studies are ongoing for confirming the detected results.
- Published
- 2024
- Full Text
- View/download PDF
8. Full genomic sequence of the HLA-DQB1*06:18:01 allele identified by next-generation sequencing.
- Author
-
Du Z and Williams CD
- Subjects
- Humans, Histocompatibility Testing methods, 5' Untranslated Regions, Base Sequence, Sequence Analysis, DNA methods, HLA-DQ beta-Chains genetics, Alleles, High-Throughput Nucleotide Sequencing methods, Exons, Introns, 3' Untranslated Regions
- Abstract
Full-length sequence of HLA-DQB1*06:18:01 covers the 5'-untranslated region (UTR), all introns and exons, and the 3' UTR., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
9. Characterisation of the novel HLA-DQB1*06:02:62 allele using short- and long-read sequencing technologies.
- Author
-
Oliveira V, Pinto J, Vianna R, Porto LC, and Secco D
- Subjects
- Humans, Sequence Analysis, DNA methods, Histocompatibility Testing methods, Brazil, High-Throughput Nucleotide Sequencing methods, Codon, Base Sequence, HLA-DQ beta-Chains genetics, Alleles, Exons
- Abstract
The novel HLA-DQB1*06:02:62 allele, first described in an individual from Brazil., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
10. Extending HLA allele sequences using next-generation sequencing technology.
- Author
-
Vinod PIM, Shruthi PS, Sharma A, Arora D, and Kour M
- Subjects
- Humans, Histocompatibility Testing methods, Sequence Analysis, DNA methods, Exons, Base Sequence, Alleles, High-Throughput Nucleotide Sequencing methods, HLA Antigens genetics
- Abstract
Extended sequences for 13 HLA alleles were found which had limited coverage previously., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
11. Introduction of the donor centre virtual crossmatch in Eurotransplant.
- Author
-
Heidt S, Kramer CSM, Haasnoot GW, Schmidt AH, Zoet YM, Claas FHJ, and Vogelaar S
- Subjects
- Humans, Tissue and Organ Procurement methods, Pancreas Transplantation methods, Europe, Isoantibodies blood, Histocompatibility Testing methods, HLA Antigens immunology, HLA Antigens genetics, Kidney Transplantation methods, Tissue Donors
- Abstract
On 24 January 2023, Eurotransplant has introduced the virtual crossmatch for kidney and pancreas allocation as a better alternative for the physical Complement Dependent Cytotoxicity (CDC) crossmatches at the donor centre, which were associated with a longer cold ischaemia time and false positive reactions. For the time being, the physical CDC crossmatch at the recipient centre will remain in place as the final histocompatibility check. While Eurotransplant is certainly not the first organ allocation organisation to introduce virtual crossmatching, several novel aspects have been introduced, such as calculation of the virtual panel reactive antibody (vPRA) on 11 loci at the second-field level in addition to the serological broad and split level, electronic HLA typing data transmission using Histoimmunogenetics Markup Language (HML) file format, and the actual virtual crossmatch based on ambiguous, second-field HLA typing of the donor on all 11 loci. This short communication will focus on these novel aspects of the virtual crossmatch in Eurotransplant., (© 2024 The Author(s). HLA: Immune Response Genetics published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
12. Two novel HLA class II alleles identified by next-generation sequencing.
- Author
-
Loginova M, Smirnova D, and Paramonov I
- Subjects
- Humans, Exons, Russia, Histocompatibility Testing methods, Base Sequence, Sequence Analysis, DNA methods, Alleles, High-Throughput Nucleotide Sequencing methods, HLA-DRB1 Chains genetics, HLA-DQ beta-Chains genetics
- Abstract
Two novel HLA class II, HLA-DRB1*13:357 and HLA-DQB1*03:525, characterised in Russian individuals., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
13. Identification of 43 novel HLA alleles by PacBio single molecule real-time sequencing in haematopoietic cell donors.
- Author
-
French AJE, Lucas JAM, Cooper MA, Marsh SGE, and Mayor NP
- Subjects
- Humans, Sequence Analysis, DNA methods, Hematopoietic Stem Cell Transplantation, High-Throughput Nucleotide Sequencing methods, Hematopoietic Stem Cells metabolism, Alleles, Tissue Donors, HLA Antigens genetics, Histocompatibility Testing methods
- Abstract
A total of 43 novel HLA alleles detected in haematopoietic cell donors using single molecule real-time DNA sequencing., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
14. Identification of the novel HLA-DRB3*03:69 allele by next-generation sequencing.
- Author
-
Molinari IF, de Oliveira AML, Massi FP, Hirata BKB, and Visentainer JEL
- Subjects
- Humans, Base Sequence, Codon, Sequence Alignment, Sequence Analysis, DNA methods, Alleles, Exons, High-Throughput Nucleotide Sequencing methods, Histocompatibility Testing methods, HLA-DRB3 Chains genetics
- Abstract
The new HLA-DRB3*03:69 allele differs from DRB3*03:01:01:03 by change of C → G in exon 3., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
15. A novel HLA-C*18 variant allele, HLA-C*18:20, identified by next-generation sequencing.
- Author
-
McLamb N, Jennemann JE, Willey P, and Liu C
- Subjects
- Humans, Codon, Mutation, Missense, Base Sequence, Sequence Analysis, DNA methods, Tissue Donors, HLA-C Antigens genetics, Alleles, High-Throughput Nucleotide Sequencing, Histocompatibility Testing methods, Exons
- Abstract
A missense nucleotide substitution at codon 95 of HLA-C*18:01:01:01 creates a novel allele HLA-C*18:20., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
16. Characterisation of the novel HLA-A*24:630 allele by sequencing-based typing.
- Author
-
Pan L, Zhang A, Zhao L, Tang W, and Fu B
- Subjects
- Humans, Codon, HLA-A24 Antigen genetics, HLA-A24 Antigen immunology, Polymorphism, Single Nucleotide, Sequence Alignment, Alleles, Base Sequence, Exons, Histocompatibility Testing methods, Sequence Analysis, DNA methods
- Abstract
HLA-A*24:630 differs from HLA-A*24:20:01:01 by one nucleotide substitution in codon 131 in exon 3., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
17. Calcium-dependent HLA-DQ epitope revealed by EDTA mediated inhibition of antibody reactions in the Luminex single antigen bead assay.
- Author
-
de Marco R, Noronha IH, Bottino LZMF, Dos Silva AAS, Liwski R, and Gerbase-DeLima M
- Subjects
- Humans, Female, Middle Aged, Isoantibodies immunology, Isoantibodies blood, Kidney Transplantation, Edetic Acid pharmacology, Edetic Acid chemistry, Epitopes immunology, Histocompatibility Testing methods, HLA-DQ Antigens immunology, Calcium
- Abstract
Complement mediated interference with the detection of antibodies targeting HLA is a known limitation of the single antigen bead (SAB) Luminex assay. Ethylenediaminetetraacetic acid (EDTA) is currently the serum treatment of choice in most histocompatibility laboratories to block complement activation by chelating calcium. The purpose of this study was to investigate a serum with an antibody reactivity to HLA-DQ6, 7, 8 and 9 molecules, in the Luminex SAB assay, that was inhibited by treatment with EDTA. Serum was from a 55-year-old highly sensitised female renal transplant candidate that contained, among others, antibodies to an epitope containing the 74EL eplet, shared by HLA-DQ6, DQ7, DQ8 and DQ9 molecules. Serum samples were treated with EDTA, dithiothreitol (DTT), or heat prior to testing by SAB assay. EDTA-treated serum was also tested after the addition of calcium chloride (CaCl
2 ). HLA-DQ-specific antibodies were isolated by adsorption/elution method using three informative donor cells and were tested in the absence or presence of EDTA. The antibody reactivity against HLA-DQ6, DQ7, DQ8 and DQ9 in the SAB assay was significantly inhibited by treating serum and eluates with EDTA and was restored by addition of CaCl2 . The study represents the first description of a calcium-dependent epitope in HLA molecules. The relevance of this finding is that the treatment of sera with EDTA could lead to false-negative reactions in the SAB assay, which may compromise virtual crossmatching., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF
18. Identification of the novel HLA-C*07:1132 allele by next-generation sequencing.
- Author
-
Galluccio T, Cerretti R, Battarra M, Giustiniani P, and Andreani M
- Subjects
- Humans, Base Sequence, Sequence Analysis, DNA methods, Sequence Alignment, Polymorphism, Single Nucleotide, Codon, HLA-C Antigens genetics, Alleles, Exons, High-Throughput Nucleotide Sequencing methods, Histocompatibility Testing methods
- Abstract
The novel HLA-C*07:1132 allele differs from HLA-C*07:01:01 by one nucleotide substitution in Exon 5., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
19. High resolution HLA genotyping with third generation sequencing technology-A multicentre study.
- Author
-
Buhler S, Nørgaard M, Steffensen R, Kløve-Mogensen K, Møller BK, Grossmann R, Ferrari-Lacraz S, and Lehmann C
- Subjects
- Humans, Software, Alleles, Genotype, Quality Control, Nanopore Sequencing methods, Genotyping Techniques methods, Histocompatibility Testing methods, High-Throughput Nucleotide Sequencing methods, HLA Antigens genetics
- Abstract
Molecular HLA typing techniques are currently undergoing a rapid evolution. While real-time PCR is established as the standard method in tissue typing laboratories regarding allocation of solid organs, next generation sequencing (NGS) for high-resolution HLA typing is becoming indispensable but is not yet suitable for deceased donors. By contrast, high-resolution typing is essential for stem cell transplantation and is increasingly required for questions relating to various disease associations. In this multicentre clinical study, the TGS technique using nanopore sequencing is investigated applying NanoTYPE™ kit and NanoTYPER™ software (Omixon Biocomputing Ltd., Budapest, Hungary) regarding the concordance of the results with NGS and its practicability in diagnostic laboratories. The results of 381 samples show a concordance of 99.58% for 11 HLA loci, HLA-A, -B, -C, -DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1, -DPA1 and -DPB1. The quality control (QC) data shows a very high quality of the sequencing performed in each laboratory, 34,926 (97.15%) QC values were returned as 'passed', 862 (2.4%) as 'inspect' and 162 (0.45%) as 'failed'. We show that an 'inspect' or 'failed' QC warning does not automatically lead to incorrect HLA typing. The advantages of nanopore sequencing are speed, flexibility, reusability of the flow cells and easy implementation in the laboratory. There are challenges, such as exon coverage and the handling of large amounts of data. Finally, nanopore sequencing presents potential for applications in basic research within the field of epigenetics and genomics and holds significance for clinical concerns., (© 2024 The Author(s). HLA: Immune Response Genetics published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
20. Identification of the novel allele HLA-DQB1*06:02:61 by next-generation sequencing.
- Author
-
Bianculli AG, Besi F, Troiano M, Giustiniani P, and Andreani M
- Subjects
- Humans, Base Sequence, Sequence Analysis, DNA methods, Polymorphism, Single Nucleotide, HLA-DQ beta-Chains genetics, Alleles, High-Throughput Nucleotide Sequencing, Exons, Histocompatibility Testing methods
- Abstract
HLA-DQB1*06:02:61 differs from HLA-DQB1*06:02:01:01 by one nucleotide substitution in exon 4-5512 G>A., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
21. Characterisation of the novel HLA-C*07:02:151 allele by sequencing-based typing.
- Author
-
Elsermans V, Cargou M, Pajot T, Top I, and Labalette M
- Subjects
- Humans, Sequence Alignment, HLA-C Antigens genetics, Alleles, Exons, Histocompatibility Testing methods, Sequence Analysis, DNA methods, Base Sequence, Codon
- Abstract
HLA-C*07:02:151 differs from HLA-C*07:02:01:01 by one nucleotide substitution in codon 166 in exon 3., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
22. Eight new variants of HLA-DQB1*03 identified by next-generation sequencing.
- Author
-
Marín Rubio LA and Ontañón J
- Subjects
- Humans, Histocompatibility Testing methods, Exons, Spain, Sequence Analysis, DNA methods, Genetic Variation, HLA-DQ beta-Chains genetics, High-Throughput Nucleotide Sequencing methods, Alleles
- Abstract
Genomic sequence of HLA-DQB1*03:01:01:60, -DQB1*03:01:01:61, -DQB1*03:01:01:62, -DQB1*03:01:01:63, -DQB1*03:02:01:23, -DQB1*03:02:01:24, -DQB1*03:02:01:25 and -DQB1*03:03:02:14 alleles in Spanish individuals., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
23. Two novel HLA-DQB1 alleles identified by next generation sequencing.
- Author
-
Loginova M, Obukhov I, and Paramonov I
- Subjects
- Humans, Histocompatibility Testing methods, Base Sequence, Sequence Analysis, DNA methods, Codon, Bone Marrow, HLA-DQ beta-Chains genetics, Alleles, High-Throughput Nucleotide Sequencing, Exons
- Abstract
Two novel HLA-DQB1 alleles, HLA-DQB1*05:01:50 and HLA-DQB1*06:486, characterised in bone marrow volunteers., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
24. Characterisation of the novel HLA-DRB1*08:126 allele by sequencing-based typing.
- Author
-
Elsermans V, Visentin J, Pajot T, Top I, and Labalette M
- Subjects
- Humans, Codon, Sequence Alignment, HLA-DRB1 Chains genetics, Alleles, Histocompatibility Testing methods, Exons, Sequence Analysis, DNA methods, Base Sequence
- Abstract
HLA-DRB1*08:126 differs from HLA-DRB1*08:04:01:01 by one nucleotide substitution in codon 152 in exon 3., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
25. The novel HLA-C*15:279 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual.
- Author
-
Li DM, Jing YY, Jia YJ, and Sun TC
- Subjects
- Humans, Sequence Alignment, Codon, East Asian People, HLA-C Antigens genetics, Alleles, Exons, Asian People genetics, Sequence Analysis, DNA methods, Base Sequence, Histocompatibility Testing methods
- Abstract
The novel HLA-C*15:279 allele differs from HLA-C*15:02:01:01 by five nucleotide substitutions in exons 4 and 5., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
26. Forming a new perspective: Post-structural approaches to determination of donor compatibility and post-transplant assessment of allograft health.
- Author
-
Nadat F and Clark B
- Subjects
- Humans, Histocompatibility Testing methods, Transplantation, Homologous, Graft Rejection immunology, HLA Antigens immunology, HLA Antigens genetics, Histocompatibility immunology, Graft Survival immunology, Tissue Donors, Allografts immunology
- Abstract
The purpose of this review is to encourage a new perspective on the question of donor-recipient compatibility and post-transplant assessment of graft health based on functional measures. The premise is that we should be better sighted on what (and how) the immune system responds toward rather than what is merely there. Continuance of the pursuit of further and better definition of antigens and antibodies is not however discouraged but seen as necessary to improved understanding of the structural correlates of functional immunity. There currently exists, in the opinion of the authors, an opportunity for histocompatibility and immunogenetics laboratories to develop and widen their scope of involvement into these new areas of laboratory activity in support and to the benefit of the transplant programmes they serve., (© 2024 John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
27. Orthanq: transparent and uncertainty-aware haplotype quantification with application in HLA-typing.
- Author
-
Uzuner H, Paschen A, Schadendorf D, and Köster J
- Subjects
- Humans, Software, Uncertainty, Sequence Analysis, DNA methods, Models, Statistical, Algorithms, Haplotypes genetics, HLA Antigens genetics, Histocompatibility Testing methods
- Abstract
Background: Identification of human leukocyte antigen (HLA) types from DNA-sequenced human samples is important in organ transplantation and cancer immunotherapy and remains a challenging task considering sequence homology and extreme polymorphism of HLA genes., Results: We present Orthanq, a novel statistical model and corresponding application for transparent and uncertainty-aware quantification of haplotypes. We utilize our approach to perform HLA typing while, for the first time, reporting uncertainty of predictions and transparently observing mutations beyond reported HLA types. Using 99 gold standard samples from 1000 Genomes, Illumina Platinum Genomes and Genome In a Bottle projects, we show that Orthanq can provide overall superior accuracy and shorter runtimes than state-of-the-art HLA typers., Conclusions: Orthanq is the first approach that allows to directly utilize existing pangenome alignments and type all HLA loci. Moreover, it can be generalized for usages beyond HLA typing, e.g. for virus lineage quantification. Orthanq is available under https://orthanq.github.io ., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
28. Histocompatibility assessment in hematopoietic stem cell transplantation: recommendations from the Italian Society for Immunogenetics and Transplantation Biology (Associazione Italiana di Immunogenetica e Biologia dei Trapianti - AIBT).
- Author
-
Crocchiolo R, Fusco C, Andreani M, Rombolà G, Falco M, Vecchiato C, Garbarino L, Mele L, Mazzi AB, Picardi A, Lombardini L, Pollichieni S, De Stefano MC, Ciceri F, Cardillo M, and Papola F
- Subjects
- Humans, Italy, Allografts, Histocompatibility, Transplantation, Homologous, Societies, Medical, Immunogenetics methods, Killer Cells, Natural immunology, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing methods, HLA Antigens immunology
- Abstract
The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) is significantly influenced by the degree of HLA histocompatibility between donor and recipient. To provide shared indications for required histocompatibility testing and interpretation before HSCT, the Italian Society for Immunogenetics and Transplantation Biology (Associazione Italiana di Immunogenetica e Biologia dei Trapianti [AIBT]) gathered members and created a working group to discuss and develop recommendations for histocompatibility assessment in HSCT.After a review of the literature and multiple panel discussions, AIBT developed up-to-date recommendations for the resolution levels of HLA typing, histocompatibility definitions of patients and donors, importance of anti-HLA antibodies, and significance of NK alloreactivity, which are reported in this document. These recommendations have been shared with the Italian Group for Bone Marrow Transplantation (Gruppo Italiano per il Trapianto di Midollo Osseo, cellule staminali emopoietiche e terapia cellulare [GITMO]) and the Italian National Center for Transplantation (Centro Nazionale Trapianti [CNT]). Notably, the increased use of HLA-mismatched transplantation (i.e., mismatched unrelated, haploidentical) in recent years has made these indications even more relevant for the standardization and improvement of quality of care.This document represents a useful instrument for health care workers involved in the field of HSCT, enhancing synergy with transplant physicians and enabling greater optimization of the available resources.
- Published
- 2024
- Full Text
- View/download PDF
29. Characterisation of the novel HLA-DRB4*01:182 allele by sequencing-based typing.
- Author
-
Blandin L, Cargou M, Wojciechowski E, Lemal R, and Rouzaire P
- Subjects
- Humans, Codon, Sequence Alignment, Alleles, Exons, Histocompatibility Testing methods, Sequence Analysis, DNA methods, HLA-DRB4 Chains genetics, Base Sequence
- Abstract
HLA-DRB4*01:182 differs from HLA-DRB4*01:03:01:01 by one nucleotide substitution in codon 172 in exon 3., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
30. Identification of the novel HLA-DRB3*02:209 allele by next-generation sequencing.
- Author
-
Lee JK, Lee S, Park JW, Lim S, and Kang ES
- Subjects
- Humans, Base Sequence, Polymorphism, Single Nucleotide, Sequence Alignment, Sequence Analysis, DNA methods, Codon, Tissue Donors, Alleles, High-Throughput Nucleotide Sequencing methods, Exons, HLA-DRB3 Chains genetics, Histocompatibility Testing methods
- Abstract
HLA-DRB3*02:209 is identical to HLA-DRB3*02:02:01:01 except for a single nucleotide substitution in exon 4., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
31. Identification of the novel HLA-B*51:413 allele by next-generation sequencing in a Chinese Han individual.
- Author
-
Pan Q, Ma X, You Y, Li Y, and Zhou X
- Subjects
- Humans, Histocompatibility Testing methods, Base Sequence, HLA-B Antigens genetics, Sequence Alignment, Sequence Analysis, DNA methods, China, East Asian People, Alleles, Exons genetics, Asian People genetics, High-Throughput Nucleotide Sequencing methods
- Abstract
The novel allele HLA-B*51:413 differs from HLA-B*51:92:02 by one nucleotide substitution in exon 3., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
32. Identification of the novel HLA-B*27:276 allele by next-generation sequencing.
- Author
-
Tiziana G, Paola G, Annalisa G, Francesca B, and Marco A
- Subjects
- Humans, Base Sequence, HLA-B27 Antigen genetics, Sequence Analysis, DNA methods, Sequence Alignment, Codon, Alleles, Exons, High-Throughput Nucleotide Sequencing methods, Histocompatibility Testing methods
- Abstract
The novel HLA-B*27:276 allele differs from HLA-B*27:05:02:05 by one nucleotide substitution in exon 1., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
33. Identification of the new allele HLA-A*24:632 in a Greek individual using next generation sequencing.
- Author
-
Mantzios P, Athanassiades T, Mantziou P, Kitsiou V, and Tsirogianni A
- Subjects
- Humans, Greece, HLA-A24 Antigen genetics, HLA-A24 Antigen immunology, Polymorphism, Single Nucleotide, Base Sequence, Sequence Analysis, DNA methods, Alleles, High-Throughput Nucleotide Sequencing methods, Exons, Histocompatibility Testing methods
- Abstract
The HLA-Α*24:632 allele differs from HLA-A*24:02:01:01 by a single nucleotide substitution in exon 2., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
34. Identification of the novel HLA-A*11:01:117 allele by next-generation sequencing.
- Author
-
He Y, Li Q, Wang F, Chen C, and Zhu F
- Subjects
- Humans, Histocompatibility Testing methods, Polymorphism, Single Nucleotide, Base Sequence, Alleles, High-Throughput Nucleotide Sequencing methods, HLA-A11 Antigen genetics, Exons
- Abstract
HLA-A*11:01:117 differs from HLA-A*11:01:01:01 by a single nucleotide substitution at position 780 A>G., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
35. Allosensitisation in NHP results in cross-reactive anti-SLA antibodies not detected by a lymphocyte-based flow cytometry crossmatch.
- Author
-
Ladowski JM, Chapman H, DeLaura I, Anwar IJ, Yoon J, Chen Z, Clark A, Chen D, Knechtle S, Jackson A, Rogers B, and Kwun J
- Subjects
- Animals, Humans, Swine, Immunoglobulin G immunology, Immunoglobulin G blood, Isoantibodies immunology, Isoantibodies blood, Transplantation, Heterologous, Histocompatibility Antigens Class II immunology, Skin Transplantation, Immunoglobulin M immunology, Immunoglobulin M blood, HLA Antigens immunology, Lymphocytes immunology, Algorithms, Cross Reactions immunology, Histocompatibility Testing methods, Flow Cytometry methods, Histocompatibility Antigens Class I immunology
- Abstract
Xenotransplantation is a potential option for individuals for whom an acceptable human allograft is unavailable. Individuals with broadly reactive HLA antibodies due to prior exposure to foreign HLA are potential candidates for a clinical xenotransplant trial. It remains controversial if allosensitisation results in the development of cross-reactive antibodies against SLA. This may require increased histocompatibility scrutiny for highly sensitised individuals prior to enrollment in a clinical trial. Serum samples were obtained from non-human primates sensitised via serial skin transplantation from maximally MHC-mismatched donor, as reported. Sera from pre- and post-allosensitisation timepoints were assessed in a flow crossmatch (FXM) for IgM and IgG binding to pig splenocytes with or without red blood cell adsorption. Xenoreactive antibodies were eluted from pig splenocytes and screened on a single antigen HLA bead assay. A MHC Matchmaker algorithm was developed to predict potential conserved amino acid motifs among the pig, NHP, and human. Our sensitised NHP model was used to demonstrate that allosensitisation does not result in an appreciable difference in xenoreactive antibody binding in a cell-based FXM. However, antibody elution and screening on single antigen HLA beads suggest the existence of potential cross-reactive antibodies against SLA. The cross-reactive IgG after allosensitisation were predicted by comparing the recipient Mamu alleles against its previous allograft donor Mamu alleles and the donor pig SLA alleles. Our study suggests that allosensitisation could elevate cross-reactive antibodies, but a more sensitive assay than a cell-based FXM is required to detect them. The MHC Matchmaker algorithm was developed as a potential tool to help determine amino acid motif conservation and reactivity pattern., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
36. Optimisation of global stem cell donor recruitment based on analysis of unsuccessful donor searches.
- Author
-
Sauter J, Bernas SN, Flaig D, Hofmann JA, Maiers M, Foeken L, Pingel J, and Schmidt AH
- Subjects
- Humans, Tissue Donors, Donor Selection methods, Unrelated Donors, Hematopoietic Stem Cell Transplantation, Gene Frequency, HLA Antigens genetics, Europe, United States, Haplotypes, Registries, Histocompatibility Testing methods
- Abstract
Despite over 41 million registered potential volunteer stem cell donors worldwide, many patients in need of a transplant do not find an HLA-matched unrelated donor or cord blood units, with the respective odds differing significantly between various populations. In this study, we analysed data of 2205 unsuccessful real-life donor searches sent to the DKMS Registry to identify populations in which further donor recruitment would be associated with particularly large patient benefits. For that purpose, we estimated haplotype frequencies of 67 donor populations at various sample sizes and entered them into two different mathematical models. These models assessed patient benefits from population-specific donor recruitment, operationalised by the number of originally unsuccessful searches that may become successful due to new donors. Consistently, across the different mathematical models and sample sizes, we obtained several countries from East and Southeast Asia (Thailand, Vietnam, China, and the Philippines) and the population of Asians in the USA as countries/populations where donor recruitment activities would be particularly beneficial for patients. We also identified various countries in Southeast and Central Europe as possible target regions for donor recruitment with above-average patient benefits. The results presented are registry-specific in the sense that they were obtained by optimising unsuccessful searches that had been sent to the DKMS Registry. Therefore, it would be desirable to apply the presented methods to a global data set that includes all unsuccessful stem cell donor searches worldwide and uses population-specific haplotype frequencies based on all donors available in the WMDA Search & Match Service., (© 2024 The Author(s). HLA: Immune Response Genetics published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
37. A novel HLA-DPA1 allele, HLA-DPA1*02:134, identified by next-generation sequencing.
- Author
-
Moya-Quiles MR and Muro M
- Subjects
- Humans, Codon, High-Throughput Nucleotide Sequencing methods, HLA-DP alpha-Chains genetics, Alleles, Histocompatibility Testing methods, Exons
- Abstract
HLA-DPA1*02:134, a novel HLA class II allele detected by next-generation sequencing., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
38. Identification of the novel HLA-DQA1*05:03:03 allele by next-generation sequencing.
- Author
-
Moya-Quiles MR and Muro M
- Subjects
- Humans, Codon, Base Sequence, Sequence Analysis, DNA methods, HLA-DQ alpha-Chains genetics, High-Throughput Nucleotide Sequencing methods, Alleles, Histocompatibility Testing methods, Exons
- Abstract
HLA-DQA1*05:03:03, a novel HLA class II allele detected by next-generation sequencing., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
39. Identification of the new allele HLA-C*04:01:01:186 in a Greek individual using next generation sequencing.
- Author
-
Mantzios P, Athanassiades T, Kouniaki D, Kitsiou V, and Tsirogianni A
- Subjects
- Humans, Greece, Polymorphism, Single Nucleotide, Exons, Base Sequence, Sequence Analysis, DNA methods, HLA-C Antigens genetics, Alleles, High-Throughput Nucleotide Sequencing methods, Introns, Histocompatibility Testing methods
- Abstract
The newly discovered HLA-C*04:01:01:186 allele differs from HLA-C*04:01:01:01 by a single nucleotide substitution in intron 3., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
40. Identification of eight new HLA class I alleles by next-generation sequencing.
- Author
-
Loginova M, Makhova O, Smirnova D, and Paramonov I
- Subjects
- Humans, Exons genetics, Sequence Analysis, DNA methods, High-Throughput Nucleotide Sequencing methods, Alleles, Histocompatibility Antigens Class I genetics, Histocompatibility Antigens Class I immunology, Histocompatibility Testing methods
- Abstract
Eight novel HLA class I alleles detected by next-generation sequencing., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
41. The novel HLA-C*04:01:01:182 allele identified in a candidate bone marrow donor by next-generation sequencing.
- Author
-
Kouniaki D, Athanassiades T, and Tsirogianni A
- Subjects
- Humans, 5' Untranslated Regions, Exons, Base Sequence, Sequence Analysis, DNA methods, Bone Marrow, Polymorphism, Single Nucleotide, Bone Marrow Transplantation, HLA-C Antigens genetics, Alleles, High-Throughput Nucleotide Sequencing methods, Tissue Donors, Histocompatibility Testing methods
- Abstract
HLA-C*04:01:01:182 differs from the HLA-C*04:01:01:06 allele by one nucleotide substitution in the 5'UTR., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
42. 4-Color Flow Cytometric Crossmatch Using Whole Blood Lysis.
- Author
-
Won DI, Lim JH, Cho JH, Kim CD, Yun WS, and Huh S
- Subjects
- Humans, HLA Antigens immunology, Isoantibodies blood, ABO Blood-Group System immunology, Leukocyte Common Antigens immunology, Kidney Transplantation, Flow Cytometry methods, Histocompatibility Testing methods
- Abstract
Background: In lymphocyte crossmatch using flow cytometry (flow cytometric crossmatch, FCXM), the conventional tricolor FCXM protocol requires a mononuclear cell isolation step. To develop a new, more streamlined protocol, we introduced whole blood lysis (WBL) and CD45 fluorescence-triggered acquisition using 4-color flow cytometry., Methods: A total of 186 donor/recipient pairs for transplantation were classified into donor-specific human leukocyte antigen (HLA) alloantibody-positive (DSA+, n = 78) and DSA-negative (DSA-, n = 108) groups. The latter group was reclassified into blood group ABO-incompatible (ABOi, n = 56) and ABO-compatible (n = 52) subgroups. The WBL FCXM protocol with CD45 V500-C was optimized using a FACSLyric cytometer (BD Biosciences) with 3 lasers. Measurements for T cells or B cells were calculated as a mean fluorescence intensity (MFI) ratio (test divided by control). WBL FCXM was compared with conventional FCXM in each group., Results: WBL FCXM showed no difference quantitatively compared with conventional FCXM, except for the B cell FCXM in the DSA- group (B cell MFI ratio: 1.06 ± 0.44 and 0.92 ± 0.41, respectively [P = .0001]). There was no ABO antibody interference in the ABOi subgroup. Similar results were observed in the qualitative determinations of FCXM as follows: 1) In the DSA+ group, the sensitivity of B cell WBL FCXM (96.2%) showed no difference compared with that of conventional FCXM (91.0%, P = .2188) and 2) In the DSA- group, the specificity of T cell WBL FCXM (96.3%) showed no difference compared with that of conventional FCXM (98.1%, P = .6250). WBL FCXM reduced the turnaround time by 50 min compared with that by conventional FCXM., Conclusions: WBL FCXM demonstrated comparable assay performance to that of conventional FCXM. Because this new FCXM protocol is simple and does not compromise assay sensitivity, it has the potential to replace the conventional method in histocompatibility laboratory settings., Competing Interests: Declaration of competing interest All the authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
43. Characterisation of the novel HLA-B*46:96 allele by next-generation sequencing.
- Author
-
Dong L, Pi W, Chen N, Zhang W, and Zhu F
- Subjects
- Humans, Exons, Histocompatibility Testing methods, Polymorphism, Single Nucleotide, Base Sequence, Sequence Analysis, DNA methods, Alleles, High-Throughput Nucleotide Sequencing methods, HLA-B Antigens genetics
- Abstract
HLA-B*46:96 differs from HLA-B*46:01:01:01 by a single nucleotide substitution at position 479 C>T., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
44. Identification of the novel HLA-A*30:221 allele by next-generation sequencing.
- Author
-
Galluccio T, Giustiniani P, Di Luzio A, Testa G, and Andreani M
- Subjects
- Humans, Base Sequence, Polymorphism, Single Nucleotide, Sequence Analysis, DNA methods, Sequence Alignment, Alleles, High-Throughput Nucleotide Sequencing methods, Exons, HLA-A Antigens genetics, Histocompatibility Testing methods
- Abstract
The novel HLA-A*30:221 allele differs from HLA-A*30:01:01:01 by one nucleotide substitution in Exon 7., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
45. Lymphocyte Crossmatch Testing or Donor HLA-DP and -DQ Allele Typing Effectiveness in Single Cord Blood Transplantation for Patients With Anti-HLA Antibodies Other Than Against HLA-A, -B, -C, and -DRB1.
- Author
-
Osada M, Yamamoto H, Watanabe O, Yamaguchi K, Kageyama K, Kaji D, Taya Y, Nishida A, Ishiwata K, Takagi S, Makino S, Asano-Mori Y, Yamamoto G, Taniguchi S, Wake A, and Uchida N
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Retrospective Studies, Adolescent, HLA-DP Antigens genetics, HLA-DP Antigens immunology, Young Adult, Aged, Tissue Donors, Lymphocytes immunology, Isoantibodies blood, HLA-DRB1 Chains genetics, Cord Blood Stem Cell Transplantation, Histocompatibility Testing methods, HLA-DQ Antigens genetics, HLA-DQ Antigens immunology, Alleles
- Abstract
Anti-human leukocyte antigen (HLA) antibodies other than those against HLA-A, -B, -C, and DRB1 are a risk factor for engraftment delay and failure, especially in cord blood transplantation (CBT). The primary objective of this study was to assess the impact of the presence of anti-HLA antibodies on CBT and to evaluate the utility of lymphocyte crossmatch testing or additional HLA-DP and -DQ typing of CB units in improving transplant outcomes. We retrospectively assessed the engraftment rates and transplant outcomes of 772 patients who underwent their first CBT at our hospital between 2012 and 2021. Donors were routinely typed for HLA-A, -B, -C, and-DRB1 alleles, and the anti-HLA antibodies of recipients were screened before donor selection in all cases. Among patients who had antibodies against other than HLA-A, -B, -C, and DRB1 (n = 58), lymphocyte crossmatch testing (n = 32) or additional HLA-DP/-DQ alleles typing of CB (n = 15) was performed to avoid the use of units with corresponding alleles. The median patient age was 57 years (16 to 77). Overall, 75.7% had a high-risk disease status at transplantation, 83.5% received myeloablative conditioning regimens, and >80% were heavily transfused. Two hundred twenty-nine of the 772 recipients (29.6%) were positive for anti-HLA antibodies. There were no statistical differences in the number of infused CD34-positive cells between the anti-HLA antibody-positive and the anti-HLA antibody-negative patients. Of the 229 patients with anti-HLA antibodies, 168 (73.3%) had antibodies against HLA-A, -B, -C, and-DRB1 (Group A), whereas 58 (25.3%) had antibodies against HLA-DP, HLA-DQ, or -DRB3/4/5 with or without antibodies against HLA-A, -B, -C, and -DRB1 (Group B). No patients in both Groups A and B exhibited donor-specific anti-HLA antibodies against HLA-A, -B, -C, and -DRB1. The neutrophil engraftment rate was lower in patients with anti-HLA antibodies than in those without antibodies (89.9% versus 94.1%), whereas nonrelapse mortality (NRM) before engraftment was higher in antibody-positive patients (9.6% versus 4.9%). In patients who received 2 or more HLA allele-mismatched CB in the host-versus-graft (HVG) direction (n = 685), the neutrophil engraftment rate was lower in the anti-HLA antibody-positive recipients than in the antibody-negative recipients with significant differences (88.8% versus 93.8%) (P = .049). Similarly, transplant outcomes were worse in the antibody-positive patients with respect to 2-year overall survival (OS) (43.1% versus 52.3%) and NRM (44.0% versus 30.7%) than in the antibody-negative patients. In contrast, the results of Group B were comparable to those of the antibody-negative patients, while those of Group A were statistically worse than the antibody-negative patients in terms of all engraftment rate (88.6%), OS (34.2%), and NRM (49.0%). The presence of anti-HLA antibodies negatively impacts engraftment, NRM, and OS in CBT. However, HLA-DP/-DQ allele typing of CB units or lymphocyte crossmatch testing could be a useful strategy to overcome poor engraftment rates and transplant outcomes, especially in patients with anti-HLA antibodies against HLA-DP, HLA-DQ, or -DRB3/4/5., (Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
46. Effects of Various Concentrations of Pronase on Flow Cytometric Crossmatching Patients Treated With Rituximab and Donor HLA-Specific Antibodies.
- Author
-
Kim TS, Oh I, Choi YJ, Nam M, Lee H, and Song EY
- Subjects
- Humans, Histocompatibility Testing methods, False Positive Reactions, Male, Tissue Donors, Female, Middle Aged, Adult, Flow Cytometry, Rituximab, Pronase metabolism, HLA Antigens immunology, B-Lymphocytes immunology, B-Lymphocytes metabolism, B-Lymphocytes drug effects
- Abstract
Background: Pronase pretreatment can reduce rituximab (RTX) interference by degrading CD20 in B-cell flow cytometry crossmatch (FCXM) testing. However, it may also reduce the assay sensitivity by degrading HLA molecules. We investigated the effects of various pronase concentrations on RTX interference and the analytical sensitivity of B-cell FCXM testing., Methods: Using 59 patient serum samples and 38 donor lymphocyte samples, we designed 97 recipient-donor pairs and divided them into three groups according to RTX use and the presence of weak-to-moderate donor HLA-specific antibody (DSA) reactions: RTX+/DSA-, RTX+/DSA+, and RTX-/DSA+. FCXM was performed after pretreating lymphocytes with six different pronase concentrations (0, 0.5, 1, 2, 3, and 4 mg/mL)., Results: With B-FCXM testing, false-positive results due to RTX in the RTX+/DSA- group markedly decreased with increasing pronase concentrations. The median channel shift values in the RTX+/DSA+ and RTX-/DSA+ groups did not significantly decrease when the pronase concentration was increased from 1 mg/mL to 2 or 3 mg/mL. All eight RTX+/DSA+ cases that were positive at 1 mg/mL pronase but negative at 2 or 3 mg/mL had mean fluorescence intensity (MFI) DSA values of less than 3,000 except for DQ5 (MFI: 5,226). With T-cell FCXM, false-positive results were observed in 2.9% of 315 FCXM tests with pronase pretreatment., Conclusions: Higher concentrations (2 or 3 mg/mL) of pronase effectively eliminated RTX interference but still carried a risk for false negativity for weak DSA reactions in B-cell FCXM. Higher pronase concentrations can be used as an auxiliary method to detect moderate-to-strong DSA reactions in RTX-treated patients.
- Published
- 2024
- Full Text
- View/download PDF
47. Separating the Wheat from the Chaff among HLA-DQ Eplets.
- Author
-
Devriese M, Lemonnier FA, Lion J, Sayegh C, Fleury E, Shofstall C, Giraldo L, Fiachetti Q, Usureau C, Miyadera H, Toutirais O, Mooney N, Lowe D, and Taupin JL
- Subjects
- Humans, Animals, Mice, Histocompatibility Testing methods, Graft Rejection immunology, Leukocytes, Mononuclear immunology, Amino Acid Sequence, HLA-DQ Antigens immunology
- Abstract
In transplantation, anti-HLA Abs, especially targeting the DQ locus, are well-known to lead to rejection. These Abs identified by Luminex single Ag assays recognize polymorphic amino acids on HLA, named eplets. The HLA Eplet Registry included 83 DQ eplets, mainly deduced from amino acid sequence alignments, among which 66 have not been experimentally verified. Because eplet mismatch load may improve organ allocation and transplant outcomes, it is imperative to confirm the genuine reactivity of eplets to validate this approach. Our study aimed to confirm 29 nonverified eplets, using adsorption of eplet-positive patients' sera on human spleen mononuclear cells and on transfected murine cell clones expressing a unique DQα- and DQβ-chain combination. In addition, we compared the positive beads patterns obtained in the two commercially available Luminex single Ag assays. Among the 29 nonverified DQ eplets studied, 24 were confirmed by this strategy, including the 7 DQα eplets 40E, 40ERV, 75I, 76 V, 129H, 129QS, and 130A and the 17 DQβ eplets 3P, 23L, 45G, 56L, 57 V, 66DR, 66ER, 67VG, 70GT, 74EL, 86A, 87F, 125G, 130R, 135D, 167R, and 185I. However, adsorption results did not allow us to conclude for the five eplets 66IT, 75S, 160D, 175E, and 185T., (Copyright © 2024 by The American Association of Immunologists, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
48. Donor Muse Cell Treatment Without HLA-Matching Tests and Immunosuppressant Treatment.
- Author
-
Minatoguchi S, Fujita Y, Niizuma K, Tominaga T, Yamashita T, Abe K, and Dezawa M
- Subjects
- Humans, Mesenchymal Stem Cell Transplantation methods, Immunosuppressive Agents pharmacology, Immunosuppressive Agents therapeutic use, HLA Antigens metabolism, Cell Differentiation, Animals, Histocompatibility Testing methods, Mesenchymal Stem Cells cytology, Mesenchymal Stem Cells metabolism
- Abstract
The strength of stem cell therapy is the regeneration of tissues by synergistic pleiotropic effects. Among many stem cell types, mesenchymal stem cells (MSCs) that are comprised of heterogenous population are widely used for clinical applications with the expectation of pleiotropic bystander effects. Muse cells are pluripotent-like/macrophage-like stem cells distributed in the bone marrow, peripheral blood, and organ connective tissues as cells positive for the pluripotent surface marker stage-specific-embryonic antigen -3. Muse cells comprise ~1% to several percent of MSCs. While Muse cells and MSCs share several characteristics, such as mesenchymal surface marker expression and their bystander effects, Muse cells exhibit unique characteristics not observed in MSCs. These unique characteristics of Muse cells include selective homing to damaged tissue after intravenous injection rather than being trapped in the lung like MSCs, replacement of a wide range of damaged/apoptotic cells by differentiation through phagocytosis, and long-lasting immunotolerance for donor cell use. In this review, we focus on the basic properties of Muse cells clarified through preclinical studies and clinical trials conducted by intravenous injection of donor-Muse cells without HLA-matching tests or immunosuppressant treatment. MSCs are considered to differentiate into osteogenic, chondrogenic, and adipogenic cells, whereas the range of their differentiation has long been debated. Muse cells may provide clues to the wide-ranging differentiation potential of MSCs that are observed with low frequency. Furthermore, the utilization of Muse cells may provide a novel strategy for clinical treatment., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
49. HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation.
- Author
-
Mayor NP and Marsh SGE
- Subjects
- Humans, Polymorphism, Genetic, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing methods, HLA Antigens genetics, HLA Antigens immunology
- Abstract
The importance of the HLA gene system in haematopoietic cell transplant outcomes was established early on and advances in both fields have led to ever increasing success of this clinical therapy. In large part, improvements in the understanding of HLA have been driven by the advancement in typing technologies. Each iteration of typing technology has improved the resolution of HLA typing, and often enabled the identification of polymorphism within the HLA loci. The discovery of the enormous amount of variation in the HLA genes, and the need to be able to characterise this for clinical HLA typing, has often resulted in a move away from one typing method to another more suited to typing of this complexity. Today, the gold standard for HLA typing are methods that can produce definitive HLA typing results., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
50. 25 years of the IPD-IMGT/HLA Database.
- Author
-
Robinson J, Barker DJ, and Marsh SGE
- Subjects
- Humans, Alleles, Software, History, 21st Century, History, 20th Century, Computational Biology methods, HLA Antigens genetics, HLA Antigens classification, Databases, Genetic, Histocompatibility Testing methods, High-Throughput Nucleotide Sequencing methods
- Abstract
Twenty-five years ago, in 1998, the HLA Informatics Group of the Anthony Nolan Research Institute released the IMGT/HLA Database. Since this time, this online resource has acted as the repository for the numerous variant sequences of HLA alleles named by the WHO Nomenclature Committee for Factors of the HLA System. The IPD-IMGT/HLA Database has provided a stable, highly accessible, user-friendly repository for this work. During this time, the technology underlying HLA typing has undergone significant changes. Next generation sequencing (NGS) has superseded previous methodologies of HLA typing and can generate large amounts of high-resolution sequencing data. This has resulted in a drastic increase in the number and complexity of sequences submitted to the database. The challenge for the IPD-IMGT/HLA Database has been to maintain the highest standards of curation, while supporting the core set of tools and functionality to our users with increased numbers of submissions and sequences. Traditional methods of accessing and presenting data have been challenged and new methods utilising new computing technologies have had to be developed to keep pace and support a shifting user demographic., (© 2024 The Author(s). HLA: Immune Response Genetics published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.